Board of directors
On June 11, 2025, five board members were elected at the Annual General Meeting. The board has appointed an audit committee and a remuneration committee. A summary of the board members is found in the table below and a presentation of each member is found below.
| Name | Board function | Audit committee | Remuneration committee |
|---|---|---|---|
| Carola Lemne | Chairperson | Chairperson | |
| Christer Nordstedt | Member | Member | |
| Gunnar Olsson | Member | ||
| Rein Piir | Member | Member | |
| Veronica Wallin | Member | Chairperson |
Carola Lemne
Chairperson, born 1958
Member of board since 2019
Education and background: MD, PhD and an associate professor at Karolinska Institute. Previously CEO of the Confederation of Swedish Enterprise (Swe: Svenskt Näringsliv) and Danderyd University Hospital, as well as president and CEO of Praktikertjänst AB and clinical research manager and manager at Pharmacia Corp. Carola Lemne has previously served on the boards of Getinge, Apoteket, MEDA, Investor and AFA Insurance, as well as board member of the foundation for strategic research ‘Statliga delegationen för klinisk forskning’, Stockholm university, the institute ‘Institutet för Näringslivsforskning’ and the Swedish Corporate Governanace Board, and chair of the board for the education council for clinical trials (Swe: Svenska Utbildningsrådet för Klinisk Prövning at Uppsala University.
Other ongoing assignments: Chair of Ung Företagsamhet Sverige and UF Support AB. Board member of Arjo AB (publ), Calgo Enterprise AB, Ramatuelle Holdings III AB (publ), Brf Munklägret nr 14, Terveystalo Oy and Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt- och lungsjukdomar.
Holdings: 10,000 Class A shares.
Considered independent of the company, its management and major shareholders.
Christer Nordstedt
born 1962
Member of board since 2023
Education and background: MD, PhD and associate professor in pharmacology and biochemistry at Karolinska Institutet. Doctoral studies with Nobel Prize winner Paul Greengard at Rockefeller University in New York.
More than twenty years of international experience as a research and business leader in the pharmaceutical industry. Held positions such as Global Chief Scientific Officer for Innovative Medicines at Teva Pharmaceuticals, Head of R&D at Orion Cooperation, Vice President at AstraZeneca, Senior Vice President at Hoffman-LaRoche and Eli Lilly. Former board member of Orion Diagnostics and Fermion and CEO of Vivesto AB. Currently CEO of Oblique Therapeutics AB (publ) and its subsidiary CINDA PHARMA AB.
Current assignments: Chairman of the Board of Wntresearch AB and Snevringe AB. Board member of CINDA PHARMA AB
Shareholding: No.
Considered independent of the company, its management and major shareholders.
Gunnar Olsson
born 1953
Member of board since 2017
CEO since 2023
Education and background: MD, PhD, associate professor at the Karolinska Institute, and honorary doctor of medicine at the Gothenburg University. Adjucnt professor at the Karolinska Institute 1998-2010. 35-years experience in life science industry. Served in leading positions in AstraZeneca for 25 years, whereof 10 years as head of the Therapy Areas Cardiovascular and Gastrointestinal in Global R&D. Been responsible for the development of seven global blockbusters/mega brands. Since 2013 served at board level and been consulting in bio-tech companies emanating from Swedish academic research.
Other ongoing assignments: Vice chair in Hjärt-Lungfonden Svenska Nationalföreningen mot hjärt- och lungsjukdomar and Bundy Academy at Lund’s University. Board member in Amplifier Tx AB, Betagenon AB, Betagenon Bio AB, Gesynta Pharma AB and Olsson Solutions AB. Principal (sw: bolagsman) in Olsson Solutions Kommanditbolag.
Shareholding: 4,000 Class A shares.
Considered independent of the company, its management and major shareholders.
Rein Piir
born 1958
Member of board since 2016
Education and background: B.Sc. Business Economics and Management, Uppsala University. 35 years’ experience in advising on capital market issues, including positions as head of research at Carnegie Investment Bank, strategist at Alecta, CFO/IR at Medivir and auditor at PricewaterhouseCoopers AB, head of IR at Oncopeptides AB and, through Piir & Partner AB assisting in investor relations at Camurus AB.
Other ongoing assignments: Chair of Piir & Partner AB. Board member L.E. Svensson Snickeri AB.
Shareholding: 36,333 Class A shares, 5,567 Class B shares, through legal entities/relatives.
Considered independent of the company, its management and major shareholders.
Veronica Wallin
born 1986
Member of board since 2023
Education and background: M.Sc. in business administration (1 year) at Stockholm University. Studies in marketing, PR, communication, and accounting at The State University of New York at New Paltz. Ten years of experience in Life Science, including through board assignments and leading positions in companies within the industry. Held positions as board member in Alligator Bioscience, CFO at the MedTech company Episurf Medical AB and the pharmacy company ApoEx AB and as an auditor at BDO. Currently CFO at the 4C Group AB.
Other ongoing assignments: Board member of Episurf Europe AB, Episurf Operations AB, Episurf IP-Management AB, Episurf DE GmbH and Episurf India Limited.
Shareholding: 2,000 Class A shares.
Considered independent of the company, its management and major shareholders.
Ongoing assignments refer to assignments registered with the Swedish Companies Registration Office as of April 30, 2025 and do not include assignments within the IRLAB group. Shareholdings refer to holdings registered in the Euroclear Sweden AB share register as of March 31, 2025, adjusted for changes known by the company up to April 30, 2025.